Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to two distinct pharmaceutical drugs, losartan and hydrochlorothiazide, which are commonly used in the management of cardiovascular conditions, particularly hypertension. Losartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that acts by inhibiting the sodium-chloride cotransporter in the distal convoluted tubules of the kidneys, resulting in increased excretion of sodium, chloride, and water, thereby reducing blood volume and blood pressure. These drugs are often prescribed individually or in fixed-dose combinations for blood pressure control and other related indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan or hydrochlorothiazide.